STOCK TITAN

Biolase Inc - BIOL STOCK NEWS

Welcome to our dedicated news page for Biolase (Ticker: BIOL), a resource for investors and traders seeking the latest updates and insights on Biolase.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biolase's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biolase's position in the market.

Rhea-AI Summary
BIOLASE, Inc. (NASDAQ: BIOL) announced a 1-for-100 reverse stock split effective July 27, 2023, with trading on a split-adjusted basis starting July 28, 2023. The split aims to raise the per-share trading price to maintain listing on the Nasdaq Capital Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
BIOLASE, Inc. (NASDAQ: BIOL) announced that its Epic Hygiene dental laser has been awarded Cellerant's 2023 Best of Class Hygiene Award. The laser is the only hygiene dental laser cleared by the FDA for laser bacterial reduction, and the award recognizes its innovative technology and high quality in the hygiene market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
none
-
Rhea-AI Summary
BIOLASE, Inc. plans to open a state-of-the-art training facility called the BIOLASE Education Center, adjacent to its global headquarters in Lake Forest, California. The center will provide dentists with hands-on training and education using BIOLASE's dental laser technology. It will offer courses on Waterlase all-tissue and Epic diode laser products, focusing on various dental disciplines. The facility aims to attract more dentists to adopt laser technology and provide better patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
none
-
Rhea-AI Summary
BIOLASE, a global leader in dental lasers, has closed its underwritten public offering of 175,000 units. Each unit consists of one share of Series H Convertible Preferred Stock and one warrant to purchase one-half of one share of Series H Convertible Preferred Stock. The purchase price for one unit was $26.00. The gross proceeds to BIOLASE from the offering are expected to be approximately $4.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-42.86%
Tags
Biolase Inc

Nasdaq:BIOL

BIOL Rankings

BIOL Stock Data

4.57M
32.39M
0.34%
8.24%
7.06%
Dental Equipment and Supplies Manufacturing
Manufacturing
Link
US
Irvine

About BIOL

biolase, inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment. biolase’s products are focused on better enabling clinicians to repair and restore patient’s dental conditions while reducing the pain, fear, and anxiety generally associated with dentistry. biolase is committed to elevating the standard of care in dentistry, while enabling clinicians to achieve better business returns.